Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S. Davids, Robert J. Soiffer, Haesook T. Kim et al.|New England Journal of Medicine|2016Cited by 595
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosisRaymond L. Comenzo, Giampaolo Merlini, Donna Reece et al.|Leukemia|2012Cited by 383
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Razelle Kurzrock, Megan Othus, Sandip Pravin Patel et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 159
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, Jonathan E. Rosenberg, Jiaoti Huang et al.|New England Journal of Medicine|2024Cited by 145
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S. Davids, Philippe Armand, Haesook T. Kim et al.|Blood|2020Cited by 98